Serine-proteases as plasminogen activators in terms of fibrinolysis

Journal of Pharmacy and Pharmacology

Volumn 64, Issue 8, 2012, Pages 1025-1039

  Flemmig, Martin ^a   Melzig, Matthias F ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Fibrinolysis; Plasmin; Plasminogen activator; Serine protease; T PA

Indexed keywords

ALPHA 2 ANTIPLASMIN; ALTEPLASE; AMEDIPLASE; ANISTREPLASE; BLOOD CLOTTING FACTOR 10A; DESMOTEPLASE; DUTEPLASE; FIBRIN; FIBRINOGEN; LANOTEPLASE; MEN 9036; MONTEPLASE; PAMITEPLASE; PLACEBO; PLASMIN; PLASMINOGEN; PLASMINOGEN ACTIVATOR; PROUROKINASE; RETEPLASE; SARUPLASE; SERINE PROTEINASE; SNAKE VENOM; STAPHYLOKINASE; STREPTOKINASE; TENECTEPLASE; THROMBIN; TISSUE PLASMINOGEN ACTIVATOR; TRANEXAMIC ACID; UNCLASSIFIED DRUG; UNINDEXED DRUG; UROKINASE; UROKINASE RECEPTOR;

ACUTE HEART INFARCTION; ANTICOAGULATION; BLEEDING DISORDER; BLOOD CLOTTING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CORONARY ARTERY THROMBOSIS; DRUG BINDING SITE; DRUG ELIMINATION; DRUG FATALITY; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; ENDOCYTOSIS; FIBRINOLYSIS; FIBRINOLYTIC THERAPY; HEART INFARCTION; HUMAN; NONHUMAN; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN FAMILY; PROTEIN ISOLATION; PROTEIN SYNTHESIS INHIBITION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW;

ANIMALS; BLOOD COAGULATION; FIBRINOLYSIS; FIBRINOLYTIC AGENTS; HUMANS; PLASMINOGEN ACTIVATORS; SERINE PROTEASES; THROMBOLYTIC THERAPY; THROMBOSIS; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 84863726837     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/j.2042-7158.2012.01457.x     Document Type: Review

References (149)

1. Nicholl S, et al,. Plasminogen activator system and vascular disease. Curr Vasc Pharmacol 2006; 4: 101-116. (Pubitemid 46785385)
2. Barrett A, et al,. Handbook of Proteolytic Enzymes. New York: Academic Press, 1998.
3. Collen D,. On the regulation and control of fibrinolysis. Thromb Haemost 1980; 43: 77-89.
4. Zeymer U, Neuhaus K,. Clinical trials in acute myocardial infarction. Curr Opin Cardiol 1999; 14: 392-402. (Pubitemid 29419611)
5. Holvoet P, et al,. A monoclonal antibody specific for Lys-plasminogen. Application to the study of the activation pathways of plasminogen in vivo. J Biol Chem 1985; 260: 12106-12111. (Pubitemid 16228372)
6. Castellino F, Ploplis V,. Structure and function of the plasminogen/plasmin system. Thromb Haemost 2005; 93: 647-654. (Pubitemid 40485399)
7. Fredenburgh J, Nesheim M,. Lys-plasminogen is a significant intermediate in the activation of Glu-plasminogen during fibrinolysis in vitro. J Biol Chem 1992; 267: 26150-26156. (Pubitemid 23014029)
8. Trexler M, et al,. Structure of the omega-aminocarboxylic acid-binding sites of human plasminogen. Arginine 70 and aspartic acid 56 are essential for binding of ligand by kringle 4. J Biol Chem 1982; 257: 7401-7406.
9. Cesarman-Maus G, Hajjar K,. Molecular mechanisms of fibrinolysis. Br J Haematol 2005; 129: 307-321. (Pubitemid 40646889)
10. Kunamneni A, et al,. Streptokinase-the drug of choice for thrombolytic therapy. J Thromb Thrombolysis 2007; 23: 9-23.
11. Doolittle R,. Structural basis of the fibrinogen-fibrin transformation: contributions from X-ray crystallography. Blood Rev 2003; 17: 33-41. (Pubitemid 36176209)
12. Nieuwenhuizen W,. Fibrin-mediated plasminogen activation. Ann N Y Acad Sci 2001; 936: 237-246. (Pubitemid 32613911)
13. Collen D, Lijnen H,. Basic and clinical aspects of fibrinolysis and thrombolysis. Blood 1991; 78: 3114-31124.
14. Tkachuk V, et al,. Involvement of urokinase and its receptor in the remodeling of normal and pathological tissue. Vestn Ross Akad Med Nauk 1998; 8: 36-41.
15. Kasai S, et al,. Proteolytic cleavage of single-chain pro-urokinase induces conformational change which follows activation of the zymogen and reduction of its high affinity for fibrin. J Biol Chem 1985; 260: 12377-12381. (Pubitemid 16228415)
16. Kohler M, et al,. Half-life of single-chain urokinase-type plasminogen activator (scu-PA) and two-chain urokinase-type plasminogen activator (tcu-PA) in patients with acute myocardial infarction. Thromb Res 1991; 62: 75-81.
17. Spiecker M, Meyer J,. Pro-urokinase for infarct therapy. Herz 1994; 19: 326-335.
18. Stump D, et al,. Purification and characterization of a novel low molecular weight form of single-chain urokinase-type plasminogen activator. J Biol Chem 1986; 261: 17120-17126. (Pubitemid 17210366)
19. Ouriel K,. Comparison of safety and efficacy of the various thrombolytic agents. Rev Cardiovasc Med 2002; 3: 17-24.
20. Blasi F,. Urokinase and urokinase receptor: a paracrine/autocrine system regulating cell migration and invasiveness. Bioessays 1993; 15: 105-111.
21. Adams D, et al,. A synthetic DNA encoding a modified human urokinase resistant to inhibition by serum plasminogen activator inhibitor. J Biol Chem 1991; 266: 8476-8482. (Pubitemid 21906534)
22. Yu Y, et al,. Construction and characterization of human prourokinase mutant. Shengwu Gongcheng Xuebao 2005; 21: 573-578.
23. Gurskii Y, et al,. Cloning and recombinant expression of a human urokinase-type plasminogen activator variant with reduced PAI-1 sensitivity for the use as a thrombolytic. Russ 2005. Patent no. RU 2247777.
24. Davidson D, et al,. Plasminogen activator activities of equimolar complexes of streptokinase with variant recombinant plasminogens. Biochemistry 1990; 29: 3585-3590. (Pubitemid 20136053)
25. Ojalvo A, et al,. Prevalence of circulating antibodies against a streptokinase c-terminal peptide in normal blood donors. Biochem Biophys Res Commun 1999; 263: 454-459. (Pubitemid 29467218)
26. Murray V, et al,. The molecular basis of thrombolysis and its clinical application in stroke. J Intern Med 2010; 267: 191-208.
27. Munger M, Forrence E,. Anistreplase: a new thrombolytic for the treatment of acute myocardial infarction. Clin Pharmacol Ther 1990; 9: 530-540. (Pubitemid 20211313)
28. Marinac J, et al,. Anistreplase: a novel thrombolytic agent for acute myocardial infarction. DICP 1990; 24: 607-615. (Pubitemid 20189010)
29. Rijken D, et al,. Purification and partial characterization of plasminogen activator from human uterine tissue. Biochim Biophys Acta 1979; 580: 140-153. (Pubitemid 10230765)
30. Rijken D, et al,. Relationship between tissue plasminogen activator and the activators in blood and vascular wall. Thromb Res 1980; 18: 815-830. (Pubitemid 10036558)
31. Emeis J,. Regulation of the acute release of tissue-type plasminogen activator from the endothelium by coagulation activation products. Ann NY Acad Sci 1992; 667: 249-258. (Pubitemid 23061588)
32. James J, et al,. Stimulated tissue plasminogen activator release as a marker of endothelial function in humans. Arterioscler Thromb Vasc Biol 2005; 25: 2470-2479.
33. Shi G, et al,. Plasmin and the regulation of tissue-type plasminogen activator biosynthesis in human endothelial cells. J Biol Chem 1992; 267: 19363-19368.
34. Wiman B, Collen D,. Molecular mechanism of physiological fibrinolysis. Nature 1987; 272: 549-550.
35. Hoylaerts M, et al,. Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. J Biol Chem 1982; 257: 2912-2919. (Pubitemid 12118804)
36. Pennica D, et al,. Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli. Nature 1983; 301: 214-221. (Pubitemid 13142222)
37. Nordt T, Bode C,. Thrombolysis: newer thrombolytic agents and their role in clinical medicine. Heart 2003; 89: 1358-1362. (Pubitemid 37311107)
38. Harris R, et al,. Tissue plasminogen activator has an O-linked fucose attached to threonine-61 in the epidermal growth factor domain. Biochemistry 1991; 30: 2311-2314.
39. Matsuo O, et al,. Thrombolysis by human tissue plasminogen activator and urokinase in rabbits with experimental pulmonary embolus. Nature 1981; 291: 590-591. (Pubitemid 11043684)
40. van Zonneveld A, et al,. On the interaction of the finger and the kringle-2 domain of tissue-type plasminogen activator with fibrin. Inhibition of kringle-2 binding to fibrin by epsilon- amino caproic acid. J Biol Chem 1986; 261: 14214-14218. (Pubitemid 17196329)
41. Verheijen J, et al,. Involvement of finger domain and kringle 2 domain of tissue-type plasminogen activator in fibrin binding and stimulation of activity by fibrin. EMBO J 1986; 5: 3525-3530.
42. Longstaff C, et al,. The interplay between tissue plasminogen activator domains and fibrin structures in the regulation of fibrinolysis: kinetic and microscopic studies. Blood 2011; 117: 661-668.
43. Ranby M,. Studies on the kinetics of plasminogen activation by tissue plasminogen activator. Biochim Biophys Acta 1982; 704: 461-469. (Pubitemid 12047952)
44. de Munk G, et al,. Binding of tissue-type plasminogen activator to lysine, lysine analogues, and fibrin fragments. Biochemistry 1989; 28: 7318-7325. (Pubitemid 19227370)
45. Weening-Verhoeff E, et al,. Involvement of aspartic and glutamic residues in kringle-2 of tissue-type plasminogen activator in lysine binding, fibrin binding and stimulation of activity as revealed by chemical modification and oligonucleotide-directed mutagenesis. Protein Eng 1990; 4: 191-198.
46. Andreasen P, et al,. Diversity in catalytic properties of single chain and two chain tissue-type plasminogen activator. Fibrinolysis 1991; 5: 207-215.
47. Tate K, et al,. Functional role of proteolytic cleavage at arginine-275 of human tissue plasminogen activator as assessed by site-directed mutagenesis. Biochemistry 1987; 26: 338-343. (Pubitemid 17022102)
48. Rijken D, et al,. Fibrinolytic properties of onechain and two-chain human extrinsic (tissue-type) plasminogen activator. J Biol Chem 1982; 257: 2920-2925. (Pubitemid 12118805)
49. Verstraete M, et al,. Pharmacokinetics and systemic fibrinogenolytic effects of recombinant human tissue-type plasminogen activator (rt-PA) in humans. J Pharmacol Exp Ther 1985; 235: 506-512. (Pubitemid 16248752)
50. Hotchkiss A, et al,. The influence of carbohydrate structure on the clearance of recombinant tissue-type plasminogen activator. Thromb Haemost 1988; 60: 255-261.
51. Browne M, et al,. A Tissue-type plasminogen activator mutant with prolonged clearance in vivo. J Biol Chem 1988; 263: 1599-1602.
52. Bassel-Duby R, et al,. Tyrosine 67 in the epidermal growth factor-like domain of tissue-type plasminogen activator is important for clearance by a specific hepatic receptor. J Biol Chem 1992; 267: 9668-9677.
53. Ahem T, et al,. Site-directed mutagenesis in human tissue-plasminogen activator. Distinguishing sites in the amino-terminal region required for full fibrinolytic activity and rapid clearance from the circulation. J Biol Chem 1990; 265: 5540-5545.
54. Larsen G, et al,. Pharmacokinetic and distribution analysis of variant forms of tissue-type plasminogen activator with prolonged clearance in rat. Blood 1989; 73: 1842-1850. (Pubitemid 19145115)
55. Lijnen H, Collen D,. Strategies for the improvement of thrombolytic agents. Thromb Haemost 1991; 66: 88-110.
56. Baruah D, et al,. Plasminogen activators: a comparison. Vascul Pharmacol 2005; 44: 1-9. (Pubitemid 41799584)
57. Gurewich V,. Fibrinolysis: an unfinished agenda. Blood Coagul Fibrinolysis 2000; 11: 401-408. (Pubitemid 30618518)
58. Collins R, et al,. ISIS-3 and GISSI-2: no survival advantage with tissue plasminogen activator over streptokinase, but a significant excess of strokes with tissue plasminogen activator in both trials. Am J Cardiol 1993; 71: 1127-1130. (Pubitemid 23126832)
59. Kuiper J, et al,. Interaction of mutants of tissue-type plasminogen activator with liver cells: effect of domain deletions. Biochem J 1996; 313: 775-780. (Pubitemid 26050807)
60. Weitz J,. Limited fibrin specificity of tissue-type plasminogen activator and its potential link to bleeding. J Vasc Interv Radiol 1995; 6: 19S-23S.
61. Kohnert U, et al,. Biochemical properties of the kringle 2 and protease domains are maintained in the refolded t-PA deletion variant BM 06.022. Protein Eng 1992; 5: 93-100.
62. Stürzebecher J, et al,. Mapping of the catalytic site of CHO-t-PA and the t-PA variant BM 06.022 by synthetic inhibitors and substrates. Protein Sci 1992; 1: 1007-1013. (Pubitemid 23009209)
63. Martin U, et al,. Pharmacokinetic and hemostatic properties of the recombinant plasminogen activator BM 06.022 in healthy volunteers. Thromb Haemost 1991; 66: 569-574.
64. Martin U, et al,. Dose-ranging study of the novel recombinant plasminogen activator BM 06.022 in healthy volunteers. Clin Pharmacol Ther 1991; 50: 429-436.
65. Smalling R, et al,. More rapid, complete, and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. RAPID Investigators. Circulation 1995; 91: 2725-2732.
66. Bode C, et al,. Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction.The RAPID II Investigators. Circulation 1996; 94: 891-898. (Pubitemid 26292837)
67. Anonymous. A comparison of reteplase with alteplase for acute myocardial infarction. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators. N Engl J Med 1997; 337: 1118-1123.
68. Keyt B, et al,. A faster-acting and more potent form of tissue plasminogen activator. Proc Natl Acad Sci USA 1994; 91: 3670-3674. (Pubitemid 24139493)
69. Cannon C, et al,. TNK-tissue plasminogen activator in acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose-ranging trial. Circulation 1997; 95: 351-356. (Pubitemid 27056198)
70. Avorn J, et al,. Therapeutic delay and reduced functional status six months after thrombolysis for acute myocardial infarction. Am J Cardiol 2004; 94: 415-420. (Pubitemid 39119988)
71. Wallentin L, et al,. Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized trial in acute myocardial infarction. Circulation 2003; 108: 135-142. (Pubitemid 36871293)
72. Malcolm A, et al,. ESPRIT: a European study of the prevention of reocclusion after initial thrombolysis with duteplase in acute myocardial infarction. Eur Heart J 1996; 17: 1522-1531. (Pubitemid 26345141)
73. Thomas S, et al,. Patenting of recombinant proteins: an analysis of tissue plasminogen activator (t-PA) in Europe, The United States and Japan. Res Policy 1995; 24: 645-663.
74. Suzuki S, et al,. Thrombolytic properties of a novel modified human tissue-type plasminogen activator (E6010): a bolus injection of E6010 has equivalent potency of lysing young and aged canine coronary thrombi. J Cardiovasc Pharmacol 1991; 17: 738-746.
75. Ueshima S, Matsuo O,. Development of new fibrinolytic agents. Curr Pharm Des 2006; 12: 849-857.
76. Kawai C, et al,. A prospective, randomized, double-blind multicenter trial of a single bolus injection of the novel modified t-PA E6010 in the treatment of acute myocardial infarction: comparison with native t-PA. E6010 Study Group. J Am Coll Cardiol 1997; 29: 1447-1453. (Pubitemid 27272436)
77. Inoue T, et al,. A new thrombolytic agent, monteplase, is independent of the plasminogen activator inhibitor in patients with acute myocardial infarction: initial results of the Combining Monteplase with Angioplasty (COMA) trial. Am Heart J 2002; 144: E5-E10.
78. Inoue T, et al,. Therapeutic potential of monteplase in acute myocardial infarction as a powerful thrombolytic agent for pretreatment of coronary intervention. Cardiovasc Drug Rev 2004; 22: 320-333. (Pubitemid 40116805)
79. Widimsky P, et al,. Multicentre randomized trial comparing transport to primary angioplasty vs immediate thrombolysis vs combined strategy for patients with acute myocardial infarction presenting to a community hospital without a catheterization laboratory. The PRAGUE study. Eur Heart J 2000; 21: 823-831. (Pubitemid 30240769)
80. Larsen G, et al,. Protein engineering of novel plasminogen activators with increased thrombolytic potency in rabbits relative to activase. J Biol Chem 1991; 266: 8156-8161. (Pubitemid 21906490)
81. Nordt T, et al,. Pharmacokinetics and pharmacodynamics of lanoteplase (n-PA). Thromb Haemost 1999; 82: 121-123. (Pubitemid 30093646)
82. Collen D, et al,. Pharmacokinetics and thrombolytic properties of deletion mutants of human tissue-type plasminogen activator in rabbits. Blood 1988; 71: 216-219. (Pubitemid 18050414)
83. den Heijer P, et al,. Evaluation of a weight-adjusted single-bolus plasminogen activator in patients with myocardial infarction: a double blind, randomized angiographic trial of lanoteplase versus alteplase. Circulation 1998; 98: 2117-2125. (Pubitemid 28527470)
84. InTIME-II Investigators. Intravenous NPA for the treatment of infarcting myocardium early: inTIME-II, a double-blind comparison of single-bolus lanoteplase vs accelerated alteplase for the treatment of patients with acute myocardial infarction. Eur Heart J 2000; 21: 2005-2013.
85. Verstraete M,. Third-generation thrombolytic drugs. Am J Med 2000; 109: 52-58. (Pubitemid 30608737)
86. Ishikawa A, et al,. Single and repeated intravenous toxicity studies of pamiteplase (genetical recombination) in rats and monkeys. J Toxicol Sci 1997; 22: 117-133. (Pubitemid 27248660)
87. Kawasaki T, et al,. Thrombolytic activity of a novel modified tissue-type plasminogen activator, YM866, in a canine model of coronary artery thrombosis. Jpn J Pharmacol 1993; 63: 9-16. (Pubitemid 23310386)
88. Agnelli G, et al,. Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP42935). Thromb Haemost 1993; 70: 294-300. (Pubitemid 23222488)
89. Müller D, et al,. Characterization and direct glycoform profiling of a hybrid plasminogen activator by matrix-assisted laser desorption and electrospray mass spectrometry: correlation with high-performance liquid chromatographic and nuclear magnetic resonance analyses of the released glycans. Biol Mass Spectrom 1994; 23: 330-338.
90. Rijken D, et al,. Clot penetration and fibrin binding of amediplase,a chimeric plasminogen activator (K2 tu-PA). Thromb Haemost 2004; 91: 52-60. (Pubitemid 38111220)
91. Guimarães A, et al,. Fibrinolytic efficacy of Amediplase, Tenecteplase and scu-PA in different external plasma clot lysis models: sensitivity to the inhibitory action of thrombin activatable fibrinolysis inhibitor (TAFI). Thromb Haemost 2006; 96: 325-330. (Pubitemid 44377816)
92. Krätzschmar J, et al,. The plasminogen activator family from the salivary gland of the vampire bat Desmodus rotundus, cloning and expression. Gene 1991; 105: 229-237.
93. Bringmann P, et al,. Structural features mediating fibrin selectivity of vampire bat plasminogen activators. J Biol Chem 1988; 270: 25596-25603.
94. Petri T, et al,. Production of vampire bat plasminogen activator DSPAα1 in CHO and insect cells. J Biotechnol 1995; 39: 75-83.
95. Ross A,. New plasminogen activators: a clinical review. Clin Cardiol 1999; 22: 165-171. (Pubitemid 29116164)
96. Mellott M, et al,. Vampire bat salivary plasminogen activator promotes rapid and sustained reperfusion without concomitant systemic plasminogen activation in a canine model of arterial thrombosis. Arterioscler Thromb Vasc Biol 1992; 12: 212-221.
97. Renatus M, et al,. Catalytic domain structure of vampire bat plasminogen activator: a molecular paradigm for proteolysis without activation cleavage. Biochemistry 1997; 36: 13483-13493. (Pubitemid 27481594)
98. Niego B, et al,. Desmoteplase-mediated plasminogen activation and clot lysis are inhibited by the lysine analogue tranexamic acid. Blood Coagul Fibrinolysis 2008; 19: 322-324. (Pubitemid 351670419)
99. Liberatore G, et al,. Vampire bat salivary plasminogen activator (desmoteplase): a unique fibrinolytic enzyme that does not promote neurodegeneration. Stroke 2003; 34: 537-543. (Pubitemid 36206361)
100. Reddrop C, et al,. Vampire bat salivary plasminogen activator (desmoteplase) inhibits tissue-type plasminogen activator-induced potentiation of excitotoxic injury. Stroke 2005; 36: 1241-1246. (Pubitemid 40798746)
101. Hacke W, et al,. The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 2005; 36: 66-73. (Pubitemid 40054177)
102. Furlan A, et al,. Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke 2006; 37: 1227-1231. (Pubitemid 43731867)
103. Hacke W, et al,. Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study. Lancet Neurol 2009; 8: 141-150.
104. Paciaroni M, et al,. Desmoteplase. Expert Opin Biol Ther 2009; 9: 773-778.
105. Liebeskind D,. Reversing stroke in the 2010s: lessons from Desmoteplase In Acute ischemic Stroke-2 (DIAS-2). Stroke 2009; 40: 3156-3158.
106. Collen D, et al,. Comparative thrombolytic and immunogenic properties of staphylokinase and streptokinase. Fibrinolysis 1992; 6: 232-242.
107. Matsuo O, et al,. Thrombolytic properties of staphylokinase. Blood 1990; 76: 925-929. (Pubitemid 20295503)
108. Lijnen H, et al,. On the mechanism of fibrin-specific plasminogen activation by staphylokinase. J Biol Chem 1991; 266: 11826-11832. (Pubitemid 21907023)
109. Collen D, et al,. On the mechanism of the activation of human plasminogen by recombinant staphylokinase. J Biol Chem 1993; 268: 8284-8289. (Pubitemid 23120419)
110. Grella D, Castellino F,. Activation of human plasminogen by staphylokinase. Direct evidence that preformed plasmin is necessary for activation to occur. Blood 1997; 89: 1585-1589. (Pubitemid 27097451)
111. Sakharov D, et al,. Interactions between staphylokinase, plasmin(ogen), and fibrin. Staphylokinase discriminates between free plasminogen and plasminogen bound to partially degraded fibrin. J Biol Chem 1996; 271: 27912-27918. (Pubitemid 26367369)
112. Sakai M, et al,. Mechanism of fibrin-specific fibrinolysis by staphylokinase: participation of α2-plasmin inhibitor. Biochem Biophys Res Commun 1989; 162: 830-837. (Pubitemid 19200913)
113. Lijnen H, et al,. On the molecular interactions between plasminogen-staphylokinase, α2-antiplasmin and fibrin. Biochim Biophys Acta 1992; 1118: 144-148.
114. Okada K, et al,. Effects of α2-plasmin inhibitor on plasminogen activation by staphylokinase/plasminogen complex. Thromb Res 1994; 76: 211-220. (Pubitemid 24327487)
115. Vanderschueren S, et al,. A randomized trial of recombinant staphylokinase versus alteplase for coronary artery patency in acute myocardial infarction. Circulation 1995; 92: 2044-2049.
116. Vanderschueren S, et al,. Thrombolytic therapy of peripheral arterial occlusion with recombinant staphylokinase. Circulation 1995; 92: 2050-2057.
117. Collen D, et al,. Polyethylene glycol-derivatized cysteinesubstitution variants of recombinant staphylokinase for single-bolus treatment of acute myocardial infarction. Circulation 2000; 102: 1766-1772.
118. Moreadith R, Collen D,. Clinical development of PEGylated recombinant staphylokinase (PEG-Sak) for bolus thrombolytic treatment of patients with acute myocardial infarction. Adv Drug Deliv Rev 2003; 55: 1337-1345. (Pubitemid 37464565)
119. Zhang Y, et al,. A novel plasminogen activator from snake venom. Purification, characterization, and molecular cloning. J Biol Chem 1995; 270: 10246-10255.
120. Gao R, et al,. Characterization of three fibrinogenolytic enzymes from Chinese green tree viper (Trimeresurus stejnegeri) venom. Toxicon 1998; 36: 457-467. (Pubitemid 28238070)
121. Park D, et al,. Expression and characterization of a novel plasminogen activator from Agkistrodon halys venom. Toxicon 1998; 36: 1807-1819. (Pubitemid 28532759)
122. Sanchez E, et al,. Biochemical characterization and molecular cloning of a plasminogen activator proteinase (LV-PA) from bushmaster snake venom. Biochim Biophys Acta 2006; 1760: 1762-1771. (Pubitemid 44692381)
123. Davami F, et al,. Expression of a novel chimeric truncated t-PA in CHO cells based on in silico experiments. J Biomed Biotechnol 2010.
124. Jiao J, et al,. Characterization of a recombinant chimeric plasminogen activator with enhanced fibrin binding. Biochim Biophys Acta 2001; 1546: 399-405. (Pubitemid 32280834)
125. Zhang L, et al,. Functional properties of a recombinant chimeric plasminogen activator with platelet-targeted fibrinolytic and anticoagulant potential. Mol Genet Metab 2004; 82: 304-311. (Pubitemid 39078710)
126. Vandamme A, et al,. Characterization of a recombinant chimeric plasminogen activator composed of a fibrin fragment-D-dimer-specific humanized monoclonal antibody and a truncated single-chain urokinase. Eur J Biochem 1992; 205: 139-146.
127. Lijnen H, et al,. Functional properties of a recombinant chimeric protein with combined thrombin inhibitory and plasminogen-activating potential. Eur J Biochem 1995; 234: 350-357.
128. Roussel B, et al,. HMGB-1 promotes fibrinolysis and reduces neurotoxicity mediated by tissue plasminogen activator. J Cell Sci 2011; 124: 2070-2076.
129. Balaraman K, Prabakaran G,. Production & purification of a fibrinolytic enzyme (thrombinase) from Bacillus sphaericus. Indian J Med Res 2007; 126: 459-464. (Pubitemid 351663603)
130. Balaraman K, Kuppusamy M,. Isolation of thrombinase from Bacillus sphaericus culture filtrates and use of the enzyme as a fibrinolytic. Eur Pat Appl 1994. Patent no. EP 624642.
131. Mihara H, et al,. A novel fibrinolytic enzyme extracted from the earthworm, Lumbricus rubellus. Jpn J Physiol 1991; 41: 461-472.
132. Siigur E, Siigur J,. Purification and characterization of lebetase, a fibrinolytic enzyme from Vipera lebetina (snake) venom. Biochim Biophys Acta 1991; 1074: 223-229.
133. Swenson S, et al,. Chimeric derivative of fibrolase, a fibrinolytic enzyme from southern copperhead venom, possesses inhibitory activity on platelet aggregation. Arch Biochem Biophys 2000; 384: 227-237. (Pubitemid 32012796)
134. Deitcher S, et al,. Alfimeprase: a novel recombinant direct-acting fibrinolytic. Expert Opin Biol Ther 2006; 6: 1361-1369. (Pubitemid 44875689)
135. Nagai N, et al,. Recombinant human microplasmin: production and potential therapeutic properties. J Thromb Haemost 2003; 1: 307-313.
136. Hunt J, et al,. Simplified recombinant plasmin: production and functional comparison of a novel thrombolytic molecule with plasma-derived plasmin. Thromb Haemost 2008; 100: 413-419.
137. Wu B, et al,. Purification and characterization of a novel fibrinolytic protease from Fusarium sp. CPCC 480097. J Ind Microbiol Biotechnol 2009; 36: 451-459.
138. Peng Y, et al,. Microbial fibrinolytic enzymes: an overview of source, production, properties, and thrombolytic activity in vivo. Appl Microbiol Biotechnol 2005; 69: 126-132. (Pubitemid 41795085)
139. Sumi H, et al,. A novel fibrinolytic enzyme (nattokinase) in the vegetable cheese Natto; a typical and popular soybean food in the Japanese diet. Experientia 1987; 43: 1110-1111.
140. Pais E, et al,. Effects of nattokinase, a pro-fibrinolytic enzyme, on red blood cell aggregation and whole blood viscosity. Clin Hemorheol Microcirc 2006; 35: 139-142. (Pubitemid 44126490)
141. Fujita M, et al,. Purification and characterization of a strong fibrinolytic enzyme (nattokinase) in the vegetable cheese natto, a popular soybean fermented food in Japan. Biochem Biophys Res Commun 1993; 197: 1340-1347. (Pubitemid 24042769)
142. Hahn B, et al,. Purification and characterization of a plasmin-like protease from Tenodera sinensis (Chinese mantis). Insect Biochem Mol Biol 2001; 31: 573-581. (Pubitemid 32373904)
143. Domsalla A, Melzig M,. Occurrence and properties of proteases in plant latices. Planta Med 2008; 74: 699-711. (Pubitemid 351880991)
144. Domsalla A, et al,. Proteolytic activity in latex of the genus Euphorbia-a chemotaxonomic marker? Pharmazie 2010; 65: 227-230.
145. Rajesh R, et al,. Comparative study on plant latex proteases and their involvement in hemostasis: a special emphasis on clot inducing and dissolving properties. Planta Med 2007; 73: 1061-1067. (Pubitemid 47401290)
146. Shivaprasad H, et al,. Cysteine proteases from the Asclepiadaceae plants latex exhibited thrombin and plasmin like activities. J Thromb Thrombolysis 2009; 28: 304-308.
147. Richter G, et al,. Activation and inactivation of human factor X by proteases derived from Ficus carica. Br J Haematol 2002; 119: 1042-1051. (Pubitemid 35463831)
148. Fonseca K, et al,. Purification and biochemical characterization of Eumiliin from Euphorbia milii var. hislopii latex. Phytochemistry 2010; 71: 708-715.
149. Zeymer U, Neuhaus K,. Thrombolysis and percutaneous transluminal coronary angioplasty in patients with acute myocardial infarction. Z Kardiol 2008; 89: IV30.40.